Laquinimod (ABR-215062), an orally available carboxamide derivative, is a potent immunomodulator which prevents neurodegeneration and inflammation in the central nervous system. Laquinimod reduces astrocytic NF-kappaB activation to protect from Cuprizone-induced demyelination. Laquinimod has the potential for relapsing remitting (RR) and chronic progressive (CP) forms of multiple sclerosis (MS, RRMS or CPMS) as well as neurodegenerative diseases research[1][2][3][4].
Molekulargewicht:
356.80
Reinheit:
99.46
CAS Nummer:
[248281-84-7]
Formel:
C19H17ClN2O3
Target-Kategorie:
Apoptosis,NF-kappaB
Anwendungsbeschreibung:
MCE Product type: Reference compound
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
